AI product development is going through a major shift. In the past, many teams focused on whether they could build a functioning model. Increasingly, the more important question is what kind of evidence foundation that model is built on. This is not just a change in language. It reflects a more mature stage of the industry. In healthcare especially, AI development is becoming more dependent on evidence-grounded data—data that is not only large in volume, but also meaningfully connected to clinical questions, real outcomes, validation logic, and future use settings.
Why is this happening? Because health AI has never been only a training problem. A model that performs well on an existing dataset does not automatically perform well in real clinical environments. What often determines whether a product can succeed over time is not only what it learned during development, but whether it understands the most important risks, limits, and consequences in the real world.
That raises the bar for data itself. In the past, saying “data matters” often meant sample size and labeling quality. Today, when we talk about evidence-grounded data, the emphasis is different. Four questions become central: Does the data truly map to the clinical problem, rather than simply being convenient for training? Can it support external validation and generalization? Is it connected to outcomes, risks, and real-world consequences? Can it support post-deployment monitoring and continued improvement? If the answer is no, even a model that looks strong in development can fail quickly in practice.
In practical terms, evidence-grounded data brings at least three major advantages to health AI. First, it helps define products around real-world needs. Many weak models are not weak because the methods are too simple. They are weak because they were defined around what was trainable rather than what was clinically meaningful. Second, it makes validation more meaningful. If the data only covers a single institution, a single workflow, or a narrow device environment, good metrics may still be local rather than durable. Third, it makes commercialization smoother. If an AI product is built from the beginning on a stronger evidence base, it becomes much easier to explain and defend to regulators, hospitals, partners, and payor-related stakeholders.
This is especially important for Chinese health AI companies and digital health teams. Many of them are not weak in algorithmic or engineering capability. The more common problem is that product definition and data strategy still remain at the stage of “build first, think later.” But if the goal is a more serious U.S. market pathway, a longer-term device trajectory, or higher-value clinical partnerships, embedding evidence-grounded data into the development logic from the start is far more effective than trying to repair the foundation later.
So why does AI product development increasingly depend on evidence-grounded data? Because the industry is beginning to understand a simple difference: data without evidence can help a model calculate, but evidence-grounded data helps a product become usable, credible, and sustainable. In health AI, that is not a nice-to-have layer. It is part of the foundation that determines how far a product can actually go.
